USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC, has launched a global registration, phase II clinical trial investigating the efficacy of a potential new breast cancer therapy called ARX788.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe